JAYME PHELPS: Open Payments
NPI 1104689447 · FREDERICK, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,528 in 57 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $2,268 · 2025 $3,528
Food & beverage: $3,528
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $802 |
| Novo Nordisk Inc | 11 | $785 |
| GlaxoSmithKline, LLC. | 3 | $247 |
| Amgen Inc. | 2 | $205 |
| Xeris Pharmaceuticals, Inc. | 4 | $201 |
| Dexcom, Inc. | 1 | $115 |
| Daiichi Sankyo Inc. | 1 | $108 |
| Hologic Sales and Service, LLC | 1 | $104 |
| Lilly USA, LLC | 6 | $104 |
| Teva Pharmaceuticals USA, Inc. | 1 | $103 |
Products named: Wegovy, BREZTRI, Ozempic, AIRSUPRA, AREXVY, FARXIGA, GVOKE HYPOPEN, DEXCOM G7 GSS (161).
Industry payments across MD — which companies pay providers there.
